GAITHERSBURG, Md., Jan. 17, 2025 — Caring Cross and Vector BioMed, Inc. announce that Boro Dropulic, Executive Director of Caring Cross and CEO of Vector BioMed, will present at Advanced Therapies Week (ATW) on January 21 and 22 in Dallas, Texas. Dr. Dropulic will share his expertise in three sessions focusing on the future of cell and gene therapies, improving access, and commercializing innovative treatments.

Session Details

1. Plenary Panel: “Innovating for the Future of Cell and Gene Therapies”
   Date: January 21, 2025
   Time: 9:00 – 10:30 CST
   Highlights: Dr. Dropulic will join a panel to discuss challenges and solutions for advancing cell and gene therapies.
2. Panel Discussion: “The CAR-T Story and the Future of Cell Therapies”
   Date: January 21, 2025
   Session Timing: 13:15 – 14:15 CST
   Overview: This session will explore CAR-T advancements and innovations in cellular therapies.
3. Workshop: “Transforming Good Science into Sustainable Business: Actionable Strategies for Commercializing Cell and Gene Therapies”
   Date: January 22, 2025
   Time: 8:00 – 9:00 CST
   Format: A workshop where Dr. Dropulic will present strategies for translating scientific breakthroughs into commercially viable and accessible solutions.

Thought Leadership from Dr. Boro Dropulic

Dr. Dropulic will discuss key issues including the high cost of CAR-T and other cellular therapies, the importance of on-site manufacturing, and global efforts to localize development and production:

• Reducing Manufacturing Costs: Lowering material costs, especially lentiviral vectors, is crucial for broader access. Vector BioMed offers GMP-grade lentiviral vectors at approximately half the cost of competitors through innovative manufacturing.
• Point-of-Care Manufacturing: Centralized manufacturing is expensive and inefficient. Decentralizing manufacturing to healthcare facilities can reduce costs and improve patient access.
• Global Access: Enabling low- and middle-income countries (LMICs) to develop and manufacture advanced therapies will address healthcare disparities. Caring Cross’s initiatives aim to localize production and ensure affordable treatments in underserved areas.

Caring Cross: Building a Global Network for Advanced Therapeutics

Through its International Affordable Advanced Therapeutics Manufacturing Network, Caring Cross collaborates globally to enhance on-site, low-cost manufacturing of cellular therapies. This network promotes equity and sustainability by:

• Strengthening manufacturing capacity and clinical trial infrastructure.
• Expanding collaboration among member organizations.
• Enabling transparent manufacturing practices.

This network helps organizations serve diverse populations and contribute to equitable access to life-saving therapies.

Vector BioMed: Transforming Lentiviral Vector Development and Rapid Production

Vector BioMed is expanding its development resources and optimizing lentiviral vector manufacturing. The company focuses on:

• Developing cost-effective solutions.
• Optimizing vector design for efficiency.
• Continuous innovation: In 2025, Vector BioMed plans to launch several new products expanding its lentiviral vector platform technology.

Vector BioMed is dedicated to innovation and cost reduction for its clients.

Connect with Caring Cross and Vector BioMed at ATW

Learn more about Vector BioMed’s lentiviral vector services at.
Discover how Caring Cross is advancing global access to therapies at.

Request a meeting with team members at ATW using the ATW Event App (), our, or via email at .

SOURCE Caring Cross